newsfilter
← Latest News
GlobeNewswire·

RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th

  • RenovoRx (NASDAQ: RNXT) CEO Shaun Bagai will present at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20, 2025, in New York, NY.
  • Bagai will provide updates on RenovoCath commercialization progress driven by market demand for the FDA-cleared device as a standalone product.
  • The presentation will cover Phase III TIGeR-PaC clinical trial results for IAG, a drug-device combination of intra-arterial gemcitabine delivered via RenovoCath for locally advanced pancreatic cancer.
  • RenovoRx will discuss a post-marketing observational registry study designed to evaluate long-term safety signals & survival outcomes for solid tumor patients using RenovoCath.
  • RenovoRx received its first commercial purchase orders for RenovoCath in December 2024, with several high-volume National Cancer Institute-designated centers initiating repeat orders.
  • The IAG product candidate holds Orphan Drug Designation for pancreatic cancer & bile duct cancer, granting seven years of market exclusivity upon FDA approval.
  • Investors may schedule one-on-one meetings with Bagai through Canaccord Genuity representatives or by contacting KCSA Strategic Communications.